@FiercePharma: Germany bans dozens of drugs made by Dr. Reddy's, Unichem, others because of issues at GVK Bio. Story | Follow @FiercePharma
@CarlyHFierce: New financing helps Anergis take allergy vaccine to Phase III. More | Follow @CarlyHFierce
> Pfizer's ($PFE) pain drug Lyrica, its top-selling product, failed a trial in patients with back pain, offering no more improvement than placebo. Report
> Novartis ($NVS) filed official plans for its third phase of layoffs in Suffern, NY; 22 employees will lose their jobs in early April. Report
> Lundbeck rolled out new data on its antidepressant Brintellix, its next-gen drug intended to replace sales lost to Cipralex generics; the study showed that Brintellix improved patients' memory performance. Report
> Alexion Pharmaceuticals says its rare disease treatment Soliris won orphan drug designation in Japan for treatment of patients with myasthenia gravis. Release
> European officials say fewer branded drugmakers struck patent settlements with generics companies in 2013, with 146 deals in Europe that year, compared with 183 in 2012. Report
> Cardiovascular medtech company HeartFlow has tapped former Johnson & Johnson ($JNJ) CEO William Weldon to serve on its board. Release
> Agios Pharmaceutiucals says it set a 1.98 million share stock offering at a price of $110.75 per share, expecting proceeds to hit $220 million. Release
Medical Device News
@FierceMedDev: Startup gains FDA clearance for breast surgery guidance system. Story | Follow @FierceMedDev
@EmilyWFierce: C.R. Bard battling bid from plaintiffs to consolidate pelvic mesh suits. More | Follow @EmilyWFierce
> St. Jude gains CE mark for first pacemaker with MultiPoint Pacing. Article
> Omron partnership to give AliveCor more retail punch. News
Biotech News
@FierceBiotech: Amicus eyes a 2015 EU filing for its rare disease drug with FDA in sight. Article | Follow @FierceBiotech
@DamianFierce: The @nytimes digs into the medicinal ketamine issue, with cameos from Naurex, Cerecor and $JNJ. More | Follow @DamianFierce
> Naurex posts the positive PhIIb data that helped it reel in $80M. Story
> Merck hits a hiccup with its new Ebola vaccine. News
> Bellicum battles for CAR-T spotlight with a $121M IPO pitch. Article
Vaccines News
> Amgen tests T-Vec's combo potential in trial with Merck's Keytruda. More
> Merck Vaccines president Gerberding leaving post for EVP role. Item
> Ebola vaccine makers Merck, GSK, J&J get legal protections in U.S. thanks to HHS declaration. Report
> Merck wins FDA approval for Gardasil follow-up. Story
> PaxVax meets primary endpoints in PhIII cholera vaccine trial. Article
Pharma Manufacturing News
> AstraZeneca closing U.S. plant, costing 180 jobs. Story
> More Novartis jobs cut in New York as plant suffers drawn-out drawdown. Report
> Romark building $110M plant in Puerto Rico. More
> Indonesia's Indofarma and Kimia combine manufacturing, supply chain strengths. News
> Indian drugmakers lambast proposed PET packaging ban. Article
And Finally... Drug-resistant superbugs could cost the global economy as much as $100 trillion by 2050, according to a review by a Goldman Sachs economist in the U.K. Report